53(top 2%)
papers
2.0K(top 1%)
citations
18(top 2%)
h-index
37(top 1%)
g-index
59
all documents
2.3K
doc citations
826
citing journals

Top Articles

#TitleJournalYearCitations
1Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case ReportsPLoS ONE2016373
2Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience2019213
3Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature2019203
4Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature2019164
5Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case seriesAnnals of the Rheumatic Diseases2017141
6Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis2018130
7Systematic review of case reports of antiphospholipid syndrome following infectionLupus2016105
8Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysisLupus2018105
9Myositis as an adverse event of immune checkpoint blockade for cancer therapySeminars in Arthritis and Rheumatism201990
10Improving treatment adherence in patients with rheumatoid arthritis: what are the options?International Journal of Clinical Rheumatology201566
11Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response CommitteesJournal of Allergy and Clinical Immunology202253
12Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapyRheumatology201949
13Adverse Events in Cancer ImmunotherapyAdvances in Experimental Medicine and Biology201745
14Arthritis risk with immune checkpoint inhibitor therapy for cancerCurrent Opinion in Rheumatology201936
15Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapyNature Communications202234
16Checkpoint inhibitor-related renal vasculitis and use of rituximab202032
17Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritisOncoImmunology202132
18Digital Patient Education and Decision AidsRheumatic Disease Clinics of North America201928
19Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitorsSupportive Care in Cancer202028
20Genetic determinants of immune-related adverse events in patients with melanoma receiving immune checkpoint inhibitorsCancer Immunology, Immunotherapy202127
21Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study ProtocolTrials201823
22Cancer immunotherapy–related adverse events: causes and challengesSupportive Care in Cancer202022
23A comprehensive scoping review to identify standards for the development of health information resources on the internetPLoS ONE201921
24Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitorsSupportive Care in Cancer202020
25Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology ViewCancers202220
26Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trialsSeminars in Arthritis and Rheumatism201719
27Sicca/Sjögren's syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR)Clinical and Experimental Rheumatology201919
28Systematic review of observational studies reporting antiphospholipid antibodies in patients with solid tumorsBlood Advances202017
29Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicitiesSupportive Care in Cancer202015
30Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicitySupportive Care in Cancer202014
31Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation202114
32Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantationArchives of Osteoporosis201813
33Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approachSeminars in Arthritis and Rheumatism202113
34Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group ReportJournal of Rheumatology201712
35A Case of Acquired Generalized Lipodystrophy Associated with Pembrolizumab in a Patient with Metastatic Malignant MelanomaAACE Clinical Case Reports202011
36Added value of combining methotrexate with a biological agent compared to biological monotherapy in rheumatoid arthritis patients: A systematic review and meta-analysis of randomised trialsSeminars in Arthritis and Rheumatism20199
37Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast CancerJournal of Bone and Mineral Research20209
38Overall survival in patients with rheumatoid arthritis and solid malignancies receiving biologic disease-modifying antirheumatic therapyClinical Rheumatology20208
39Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting SystemJournal of Immunotherapy and Precision Oncology20198
40Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid ArthritisJournal of Rheumatology20197
41Utilization of biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis and cancerClinical Rheumatology20207
42Aromatase inhibitor-induced inflammatory myopathies: A case seriesJoint Bone Spine20226
43Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologistsExpert Review of Clinical Immunology20195
44Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustineJournal of Oncology Pharmacy Practice20203
45Ex Vivo Interferon Gamma Production by Peripheral Immune Cells Predicts Survival in Lung AdenocarcinomaClinical Lung Cancer20192
46Genetic determinants of adverse events in cancer patients receiving immune checkpoint inhibitors.Journal of Clinical Oncology20192
47OP0197 Rheumatic and musculoskeletal adverse events associated with immune checkpoint inhibitors: data mining of the us food and drug administration adverse event reporting system20182
48Calcium and Vitamin D Supplements and Fractures in Community-Dwelling AdultsJAMA - Journal of the American Medical Association20181
49Quality appraisal of educational websites about osteoporosis and bone healthArchives of Osteoporosis20211
50Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic CholangiocarcinomaJournal of Immunotherapy and Precision Oncology20221